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deaths after thoracoabdominal aneurysm repair are the
direct result of bleeding complications.2,3 In addition, 5%
to 8% of patients require reoperation for bleeding in the
early postoperative period, a complication which greatly
increases the risk of perioperative mortality.2-4 Such bleed-
ing usually results from a diffuse coagulopathy unassoci-
ated with distinct identifiable sites of surgical bleeding.
The etiology of this coagulopathy is controversial. In
the late 1980s, Cohen and colleagues demonstrated the
presence of disseminated intravascular coagulation (DIC)
after 60 and 90 minutes of SC AXC in a canine model.5
Shunting blood to the superior mesenteric artery during
clamping prevented these changes, suggesting a major
causative role for gut ischemia.6 The diagnosis of DIC in
these experiments was based on prolongation of the pro-
thrombin time (PT) and partial thromboplastin time
(PTT) and a decrease in platelet (PLT) and serum fibrino-
gen (FBG) levels after SC AXC. These early studies have
been criticized because of the lack of specificity of the
coagulation studies used as a means of diagnosing DIC;
more direct biochemical markers of thrombosis and fibri-
Aortic cross-clamping (AXC) proximal to the celiac
trunk is used during operations on the thoracoabdominal
aorta for both aneurysmal and occlusive disease and less
frequently during surgery for trauma and resuscitation.
Major complications after supraceliac (SC) AXC result
from vital organ ischemia, including the spinal cord with
paraparesis/paraplegia, the kidneys with renal insuffi-
ciency/failure, and the viscera with liver failure, ischemic
enterocolitis, or the development of coagulopathy.1
Earlier reports have documented that 12% to 38% of early
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Purpose: The causative role of consumptive coagulopathy in the development of bleeding complications after supraceliac
(SC) aortic cross-clamping (AXC) has been challenged by recent reports that ascribe this coagulopathy to primary fi-
brinolysis. This theory is made on the basis of evidence that tissue plasminogen activator (t-PA) antigen (Ag) levels
increase after SC AXC. However, t-PA Ag levels reflect both active and inactive (bound to serum t-PA inhibitors) forms
of serum t-PA, and elevations confirm the presence of fibrinolysis only in conjunction with an increase in t-PA activity.
Methods: To investigate the etiology of this coagulopathy, we submitted eight pigs to SC AXC and six pigs to infrarenal
(IR) AXC for 30 minutes. Blood was drawn from the portal vein, the hepatic vein, and the carotid artery before AXC,
just before unclamping, and 5, 30, and 60 minutes after unclamping. Prothrombin time (PT), partial thromboplastin
time (PTT), fibrinogen (FBG), platelets (PLT), thrombin-antithrombin complexes (TAT), t-PA Ag, t-PA activity, plas-
minogen activator inhibitor-1 (PAI-1), and α2-antiplasmin (AP) activities were measured. Statistical analysis was per-
formed by using repeated measures analysis of variance and t tests.
Results: The PT did not differ between the two groups at any point. After unclamping, in the SC group there was a
drop in PLT levels (P = .005), a decrease in FBG levels (P < .001), and a trend toward PTT prolongation (P = .06)
compared with baseline. In contrast, there were no changes in PTT, PLT levels, or FBG levels in the IR group. TAT, a
serum marker of thrombin generation, increased with SC AXC (P = .04), remained elevated 5 minutes after unclamp-
ing (P = .08), and returned to normal 30 minutes after unclamping. In contrast, TAT levels did not change in the IR
control group. In the SC AXC group, the TAT levels did not differ between the three test sites at any time. SC AXC
was associated with an increase in t-PA Ag just before unclamping (P < .001) and 5 minutes after unclamping (P =
.002), but IR AXC was not. t-PA activity levels decreased in both experimental groups 30 and 60 minutes after
unclamping. Levels of α2-AP activity decreased to a similar degree in both groups after unclamping when compared
with baseline.
Conclusion: Thirty minutes of SC AXC results in intravascular thrombosis that cannot be localized to the ischemic vis-
ceral circulation. This intravascular thrombosis is associated with consumption of clotting factors. Thirty minutes of
SC AXC causes an activation of fibrinolytic pathways that does not result in a hyperfibrinolytic state. An increase in t-
PA Ag without a rise in t-PA activity does not represent true fibrinolysis, but rather an increase in the bound, inactive
forms of serum t-PA. Both IR and SC AXC result in decreased fibrinolytic activity (“fibrinolytic shutdown”) after
release of the aortic clamp. (J Vasc Surg 2002;35:100-8.)
nolysis were not available at that time. More recently, Illig
and associates ascribed the development of bleeding com-
plications with SC AXC to the induction of a primary fi-
brinolytic state. According to this theory, fibrinolysis
results from increased production of tissue plasminogen
activator (t-PA) in the ischemic mesenteric circulation and
reduced t-PA clearance by the nonperfused liver.7 The
diagnosis of fibrinolysis in Illig’s study, however, was made
on the basis of the presence of elevated t-PA antigen (Ag)
levels; t-PA activity was not measured. Recent data have
proven that elevated t-PA Ag levels alone can be mislead-
ing in determining the presence of a fibrinolytic state,
because Ag levels reflect both the active (free) and the
inactive (bound to serum inhibitors like plasminogen acti-
vator inhibitor-1 [PAI-1]) forms of serum t-PA.8,9
To further investigate the etiology of this coagulopa-
thy, we studied the hemostatic changes associated with
both SC and infrarenal (IR) AXC. A porcine model was
chosen for study, because of the known similarities of this
species’ coagulation physiology to that of humans.10,11
METHODS
Protocol. Market pigs weighing between 25 and 35
kg were tested for von Willenbrand disease before selection
for the study. After sedation and induction of general endo-
tracheal anesthesia with 1% to 2% isofluorane, a right neck
cutdown was performed for the placement of monitoring
and sampling catheters. A 7F pulmonary artery catheter
was advanced through the external jugular vein to ensure
optimal hemodynamic monitoring and guide fluid resusci-
tation during the experiment. An arterial line was placed in
the carotid artery, and with fluoroscopic guidance, a 5F
catheter was advanced through the external jugular vein
into a hepatic vein. A rectal probe was used to monitor the
animal’s temperature, and normothermia was maintained
throughout the experimental protocol with a heating blan-
ket. Maintenance intravenous fluids consisted of Lactated
Ringers solution at a rate of 5 to 10 mL/kg/h, with
boluses as necessary to ensure hemodynamic stability. The
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hematocrit level was measured throughout the experiment
to monitor fluid-induced hemodilution.
Through a midline abdominal incision, the aorta was
dissected and controlled above the celiac trunk, just below
the renal arteries and just above the aortic trifurcation. A
5F single lumen catheter was secured in the portal vein
through a pancreatic venous tributary. Eight animals
underwent aortic clamping above the celiac trunk and just
above the aortic trifurcation (SC group), and six animals
underwent aortic clamping just below the renal arteries
and above the trifurcation (IR group). Both groups
underwent clamping for 30 minutes, followed by
unclamping and observation for 1 hour. This clamp-time
was chosen because it approaches the SC clamp-time
reported in clinical series in the literature.1,7 No heparin
was given before cross-clamping. Blood samples were
obtained from the portal vein, the hepatic vein, and the
arterial line before application of the clamps, before release
of the clamps, and 5, 30, and 60 minutes after the release
of the clamps (Fig 1). After the withdrawal of the last
blood specimen, the animals were killed according to insti-
tutional protocol. An autopsy was performed to verify the
correct placement of the hepatic vein catheter.
The study was approved by the Henry Ford Hospital
Care of Experimental Animals Committee and conformed
to the “Guide for the Care and Use of Laboratory
Animals.”
Blood tests. Blood samples were collected in tubes
containing 0.5 mL of 0.5 mol/L citrate buffer, pH 4.3
(Stabilyte, Biopool International, Ventura, Calif), 0.5 mL
of 0.11 mol/L sodium citrate (BD Vacutainer, Franklin
Lakes, NJ), and 15% (K3) ethylenediamine tetraacetic acid
(BD Vacutainer). Samples were transported immediately
after collection (at room temperature) to the laboratory
for processing. Plasma was isolated within 30 to 60 min-
utes by means of centrifugation at 1500 g for 15 minutes,
Fig 1. Time points for blood sampling.
Fig 2. Platelet (PLT) count in the supraceliac (SC) and infrarenal
(IR) aortic cross-clamping (AXC) groups. PLT count was cor-
rected for dilution with the hematocrit (Hct).
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aliquoted, and frozen at –30°C. Before freezing the cit-
rated aliquots for the specialized assays, the samples were
screened for basic coagulation tests including PT, PTT,
and FBG. PLT count and hematocrit level were deter-
mined by using the Coulter AcT8 (Coulter Corporation,
Miami, Fla). The sodium citrated samples were used to
measure thrombin-antithrombin complexes (TAT) by
using the Enzygnost TAT micro, enzyme immunoassay
(Dade Behring, Marburg, Germany). An enzyme-linked
immunosorbent assay (TintElize t-PA, Cat# 1105,
Biopool International) was used for quantitative determi-
nation of t-PA Ag. Assessment of t-PA and plasminogen
activator inhibitor-1 (PAI-1) activities was accomplished
by using a chromogenic assay (Spectrolyze/ fibrin, Cat#
101101, Biopool International). Activity of α2-antiplas-
min (α2-AP) was measured by using the STA-Stachrom
Antiplasmin chromogenic assay (Cat# 00659, Diagnostica
Stago, Asnieres-Sur-Seine, France).
Statistical analysis. Results are expressed as the mean
plus or minus the SEM. Analysis of variance (ANOVA)
with repeated measures was used as a means of analyzing
the experimental group and time effects for each parame-
ter. First, the simultaneous effect of clamp site (group) and
time was tested. If this simultaneous interaction was not
significant, then the effects of clamp site (group) and time
on the individual parameter were studied separately. When
significant group or time or both interactions were
observed (P < .05), Student t tests were used as a means
of comparing the two groups at each point. Paired t test-
ing was used as a means of comparing values from each
point to baseline, within each experimental group.
Hochberg’s method was used as a means of adjusting the
α level for multiple comparisons.
RESULTS
Values presented are systemic (arterial samples), unless
otherwise indicated.
Hematocrit. There was a decrease in the hematocrit
value after the release of the aortic cross-clamp in both
experimental groups (P < .001 for both). There was no
significant difference in the hematocrit values between the
two groups at any time.
Basic tests of coagulation function. In both experi-
mental groups, there was a significant prolongation of the
PT from baseline after unclamping (P < .001); however,
there was no difference in the PT between the two groups
at any point. Although significant group (P = .013) and
time (P = .015) effects on the PTT were revealed by
means of ANOVA, the only significant difference detected
by means of t tests was a longer PTT in the SC group
(20.4 ± 1.1) compared with that in the IR control group
(16.2 ± 0.2) 30 minutes after unclamping (P = .006).
There was a significant group/time effect on PLT
with ANOVA (P = .022). In the SC group, the serum PLT
count decreased from baseline 30 minutes after unclamp-
ing (P = .005), in contrast with that in the IR control
group (Fig 2). Similarly, serum FBG levels showed a sig-
nificant time/group effect with ANOVA (P = .001). In
the SC group, the serum FBG levels decreased from base-
line 5 (P < .001), 30 (P < .001), and 60 minutes (P =
.006) after unclamping. IR FBG levels did not differ from
baseline throughout the course of the experiment (Fig 3).
Fig 3. Fibrinogen (FBG) levels in the supraceliac (SC) and infrarenal (IR) aortic cross-clamping (AXC)
groups. FBG was corrected for dilution with the hematocrit (Hct).
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Fig 4. Thrombin-antithrombin complexes (TAT) in the supraceliac (SC) and infrarenal (IR) aortic cross-
clamping (AXC) groups.
Fig 5. Tissue plasminogen activator (t-PA) activity (Act) in the supraceliac (SC) and infrarenal (IR) aor-
tic cross-clamping (AXC) groups.
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PLT and FBG values were corrected for dilution by using
the hematocrit value.
Markers of thrombosis. There was a significant
group/time interaction in TAT levels in the course of the
experiment (ANOVA, P = .009). TAT levels increased
from baseline in the SC group during the period of clamp-
ing (P = .03), but this difference was considered to be
marginal when adjusting the α level for multiple compar-
isons (Fig 4). The TAT levels did not change in the IR
control group. There was no difference in TAT levels in
the SC animals between the three sampling sites (portal
vein, hepatic vein, carotid artery) at any time.
Markers of fibrinolysis. The effect of group/time
on t-PA activity was not significant with ANOVA (P =
.294). t-PA activity decreased significantly with time in
both groups (ANOVA, P = .002). In the SC group, t-PA
activity levels were lower 30 (P = .03) and 60 minutes (P
= .04) after unclamping, when compared with baseline;
these differences were marginal, however, when adjusting
the α level for multiple comparisons. In the IR group, t-
PA activity was significantly lower than baseline 60 min-
utes after unclamping (P = .007; Fig 5). t-PA activity was
higher in the SC group than the IR control group 30 min-
utes after unclamping (P = .002), but both values were
lower than baseline at this point. There was a significant
group/time effect on t-PA Ag (ANOVA, P < .001). SC
clamping was associated with an increase in t-PA Ag levels
that peaked just before unclamping, declined 5 minutes
after unclamping, and returned to baseline 30 minutes
after unclamping (Fig 6). At the point of maximal t-PA Ag
elevation (just before unclamping), the t-PA Ag levels
were higher in the portal vein (9.6 ± 1.9 ng/dL) than in
the hepatic vein (6.5 ± 1.2 ng/dL; P = .007) or the
carotid artery (8.0 ± 1.3 ng/dL; P = .057). IR AXC was
not associated with a significant elevation in t-PA Ag lev-
els at any time (Fig 6).
There was a significant group/time interaction in PAI-
1 activity (P = .013). PAI-1 activity decreased progres-
sively during the period of AXC as long as 30 minutes
after release of the SC clamp, although this decrease only
reached statistical significance in the hepatic vein samples
and not in the portal vein or arterial samples (Figs 7 and
8). Arterial PAI-1 activity increased 60 minutes after
unclamping when compared with baseline (25.0 ± 1.8 vs
18.3 ± 1.3), but this increase was marginal (P = .04). PAI-
1 activity remained unchanged in the IR animals (Fig 8).
For α2-AP activity, only time had a significant effect
(ANOVA, P < .001). The α2-AP activity decreased simi-
larly in both experimental groups 5, 30, and 60 minutes
after release of the aortic clamps (Fig 9). The drop in α2-
AP activity was not significantly different in the two
groups at any time.
DISCUSSION
Thirty minutes of SC AXC caused activation of the
coagulation cascade, with intense thrombin generation
that subsided 30 minutes after unclamping. This activation
was associated with a decrease in serum FBG levels and a
drop in PLT at various intervals after unclamping. In addi-
tion, 30 minutes of SC AXC was associated with activation
of fibrinolytic pathways (as evidenced by a transient rise in
t-PA Ag and an initial drop in PAI-1 activity) that did not
Fig 6. Tissue plasminogen activator (t-PA) antigen (Ag) in the supraceliac (SC) and infrarenal (IR) aor-
tic cross-clamping (AXC) groups.
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result in the induction of a significant fibrinolytic state;
serum t-PA activity did not increase significantly when
compared with baseline values. These data strongly sug-
gest that SC clamping results in the induction of a proco-
agulant state that leads to consumption of clotting factors.
Is this the DIC originally suggested by Cohen?5
DIC is a complex reaction to tissue damage.12-14 An
insult results in widespread activation of the coagulation cas-
cade with thrombin generation and subsequent clot forma-
tion with or without secondary fibrinolysis. Microvascular
thrombosis can lead to end-organ damage. Bleeding results
from clotting factor and PLT consumption (coagulopathy
caused by factor depletion), when it occurs, from secondary
fibrinolysis, or from a combination of factor depletion and
increased fibrinolysis.13,14 In some situations, secondary fi-
brinolysis is accentuated and is the predominant clinical
manifestation of DIC; a classic example of this form of DIC
is acute promyelocytic leukemia, in which bleeding compli-
cations caused by an increased fibrinolytic state are common,
but widespread microvascular thrombosis is the predomi-
nant finding at autopsy.14 Other types of DIC are associated
with impaired fibrinolysis. Microangiopathic hemolytic ane-
mia, for example, results in widespread activation of coagu-
lation with down-regulation of fibrinolysis; clinical symp-
toms result from end-organ thrombotic complications (eg,
cerebral ischemia, renal failure).14 DIC is a confusing term
because it does not accurately describe the alterations in
hemostasis that are responsible for the development of coag-
ulopathic bleeding. This project was designed as a means of
separately analyzing thrombosis and fibrinolysis to systemat-
ically investigate the pathophysiology of the coagulopathy
associated with SC AXC.
In pigs that were not given heparin, SC AXC clearly
causes activation of the coagulation cascade. The exact
mechanism that triggers this activation is unknown, but the
increase in TAT levels during cross-clamping, with a return
to baseline 30 minutes after unclamping, strongly implicates
tissue ischemia. Adam and colleagues observed a similar
prothrombotic state in patients with ruptured IR abdomi-
nal aortic aneurysms.9 They attributed the induction of this
state to whole body hypoperfusion as a result of hemor-
rhagic shock. Recent bench work has demonstrated that a
decrease in tissue oxygen concentrations alters the local
endothelial cell milieu to favor thrombosis, with monocyte
activation playing a central role in this process.15,16 The lack
of significant thrombin generation during clamping in the
IR control group is somewhat surprising, but may relate to
a reduced ischemic tissue burden compared with SC clamp-
ing, better collateral pathways, or both.
Elevation of TAT levels to similar degrees in the three
vascular beds studied is also surprising. One would expect
greater increases in the ischemic tissue beds (portal vein
and hepatic vein samples) than in the non-ischemic tissue
beds (carotid artery samples). Two possible explanations
exist. First, thrombin could indeed be generated in the
ischemic tissue beds, where it is locally inactivated by
antithrombin, but the TAT complexes generated are dis-
persed systemically. Alternatively, widespread systemic
activation of coagulation even in non-ischemic tissues
could be triggered by humoral factors generated during
SC clamping.
The potential clinical implications of such intravascu-
lar coagulation are well recognized. Microvascular throm-
bosis has been associated with the development of adult
Fig 7. Hepatic vein plasminogen activator inhibitor (PAI-1) activity (Act) in the supraceliac (SC) aortic
cross-clamping (AXC) groups.
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Fig 8. Plasminogen activator inhibitor (PAI-1) activity (Act) in the supraceliac (SC) and infrarenal (IR)
aortic cross-clamping (AXC) groups.
Fig 9. α 2 antiplasmin (a2-AP) activity in the supraceliac (SC) and infrarenal (IR) aortic cross-clamping
(AXC) groups.
respiratory distress syndrome,17 myocardial ischemia,18,19
multiple organ system failure,9,17,20,21 and death.17,20,21
The repair of aneurysms originating above the origins of
the renal and visceral arteries frequently requires SC AXC
and is associated with increased morbidity and mortality
rates compared with those of IR aneurysm repair. Hines
and Chorost22 reviewed their experience with SC AXC in
proximal abdominal aortic aneurysm repair and reported
that of the six patients who died perioperatively, one had
an acute myocardial infarction and four died of multiple
organ system failure. Whether widespread intravascular
coagulation is in part responsible for this increased inci-
dence of thrombotic complications after operations
requiring SC clamping is unclear, but it certainly seems
plausible.
In this porcine model of SC AXC, there was evidence
of clotting factor consumption after unclamping. FBG lev-
els decreased in the SC group 5 minutes after unclamping
and remained low after 30 and 60 minutes. The PLT count
decreased similarly after unclamping in the SC animals; this
reduction was significant only at 30 minutes. Similar find-
ings have been reported by other authors.2,5,23 Gertler et
al2 found a significant reduction in coagulation factors 30
minutes after aortic clamping in patients undergoing tho-
racoabdominal aneurysm repair, compared with those in
patients undergoing IR aneurysm repair. These changes
subsided by the end of the operation.
The PT increased in both groups in the course of the
experiment. Illig et al7 reported similar PT prolongation
in patients undergoing SC and IR AXC and attributed
these changes to hemodilution. The PTT increased in the
SC group 30 minutes after unclamping compared with
that in the IR control group. The etiology of this PTT
prolongation is not clear. If hemodilution alone was
responsible for this increase, one would expect similar
PTT prolongation in the IR control subjects. The PTT,
however, did not change in the IR control group. This
trend toward PTT prolongation may be a reflection of
clotting factor consumption associated with SC AXC.
Further studies are necessary to clarify this point.
Although 30 minutes of SC AXC did cause activation
of fibrinolytic pathways (as evidenced by an increase in t-
PA Ag with a parallel decrease in PAI-1 activity), this acti-
vation did not result in a fibrinolytic state. There was only
a transient and non-significant rise in t-PA activity in this
group. Furthermore, α2-AP activity (the main serum
inhibitor of plasmin) did not differ between the SC ani-
mals and the IR control animals. If SC clamping was asso-
ciated with increased fibrinolysis, one would expect a
much greater drop in α2-AP activity than in the IR group
to compensate for the increased plasmin generated. There
was actually a decrease in serum fibrinolytic activity (t-PA
activity) in both groups after release of the cross-clamp. A
transient rise in fibrinolytic activity after ischemia with
subsequent depression is a well-recognized phenome-
non.15,24,25 In addition, reduced t-PA activity and
increased PAI-1 activity have been reported in the imme-
diate postoperative period in patients undergoing infrain-
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 1 Anagnostopoulos et al 107
guinal bypass grafting procedures for severe limb
ischemia.26 This postoperative alteration in endogenous
fibrinolytic activity results from an imbalance between
activators and inhibitors of fibrinolysis and has been
described in patients undergoing a variety of surgical pro-
cedures. This “fibrinolytic shutdown” has been implicated
in the development of a number of postoperative throm-
botic complications (eg, deep vein thrombosis and early
arterial bypass graft occlusion).26-29
The results of this study conflict with the conclusions
of Illig et al,7 who ascribed the coagulopathy of SC AXC
to the induction of primary fibrinolysis. These investigators
found that a fibrinolytic state developed in patients under-
going SC AXC, as evidenced by decreased euglobulin clot
lysis times, reduced α2-AP levels, and elevated t-PA Ag lev-
els. We did not measure euglobulin clot lysis times in our
study, because this test has been replaced in our institution
with more reliable molecular markers of fibrinolysis (ie, 
t-PA activity, PAI-1 activity, and α2-AP activity). As men-
tioned earlier, we did not find any difference in the α2-AP
activity between the two study groups, in contrast to Illig
et al’s results. The cause of this discrepancy is unclear. In
our study, t-PA Ag increased substantially in the animals in
the SC group after AXC and returned to baseline 30 min-
utes after clamp release, a result similar to that reported by
Illig’s group.7 Recent work has documented that serum t-
PA Ag is not an accurate marker of fibrinolytic activity
because it reflects both the active and inactive forms (eg,
bound to serum inhibitors) of serum t-PA.9,30
t-PA is removed from the blood by the liver and by
reaction with serum inhibitors, primarily PAI-1 to form
inactive (t-PA/PAI-1) complexes. The liver removes 70%
to 90% of active t-PA during a single pass.8,31 Plasma clear-
ance of active t-PA is faster than the clearance of the t-
PA/PAI-1 complex. In situations in which there is
increased formation of t-PA/PAI-1 complex, the complex
accumulates and contributes to the measured concentra-
tion of t-PA Ag. Thus, a rise in serum t-PA Ag does not
necessarily equate with the presence of a fibrinolytic state.8
It seems reasonable to assume that liver hypoperfusion
caused by SC clamping does result in decreased hepatic
clearance of serum t-PA, as suggested by Illig et al.7 In this
scenario, PAI-1 may well become the primary mechanism
of t-PA inactivation, hence the increase in t-PA Ag and
parallel decrease in PAI-1 activity observed in this study.
The dramatic rise in t-PA Ag seen after 30 minutes of
SC clamping raises the possibility that a fibrinolytic state
could develop with longer periods of SC aortic occlusion.
Liver hypoperfusion during SC clamping results in
decreased hepatic clearance of t-PA and increases the
importance of t-PA inactivation by serum inhibitors (like
PAI-1). Increased t-PA generation by the ischemic gut
(the highest regional levels of t-PA Ag during SC AXC
were found in the portal vein) could temporarily over-
whelm serum inhibitory mechanisms and induce a fibri-
nolytic state with the potential for significant bleeding
complications, as suggested by Illig et al. Future studies
should address this issue.
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In conclusion, our data show that 30 minutes of SC
AXC results in systemic intravascular coagulation that is
associated with consumption of clotting factors. Thirty
minutes of SC AXC does not result in significant primary
fibrinolysis. Both SC and IR AXC result in downregula-
tion of fibrinolysis after unclamping. On the basis of this
data, the generalized use of antifibrinolytic agents, as pro-
posed by some authorities for treatment of the coagulopa-
thy associated with SC AXC, does not seem reasonable.
The use of an antifibrinolytic agent in a patient who is
bleeding from factor depletion after activation of intravas-
cular coagulation could lead to unopposed thrombosis
with potentially devastating ischemic consequences.
Anticoagulation with heparin may, however, decrease the
amount of intravascular thrombosis, protect from the con-
sumption of clotting factors, and thus prevent the devel-
opment of bleeding complications.
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